Fulcrum Therapeutics, Inc.’s Price-to-Sales Ratio at a glance
Fulcrum Therapeutics, Inc. reports price-to-sales ratio of 3.6x for Dec 2024. The prior period recorded 147.5x (Dec 2023). Year over year the metric moved −143.9 (−97.5%). The rolling three-period average stands at 67.6x. Data last refreshed Dec 7, 2025, 2:51 AM.
Latest reading
3.6x · Dec 2024
YoY movement
−143.9 (−97.5%)
Rolling average
67.6x
Current Price-to-Sales Ratio
3.6x
−143.9
−97.5%
Rolling average
67.6x
Latest Value
3.6x
Dec 2024
YoY Change
−143.9
Absolute
YoY Change %
−97.5%
Rate of change
3-Period Avg
67.6x
Smoothed
Narrative signal
Fulcrum Therapeutics, Inc.’s price-to-sales ratio stands at 3.6x for Dec 2024. Year-over-year, the metric shifted by −143.9, translating into a −97.5% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How price-to-sales ratio shapes Fulcrum Therapeutics, Inc.'s story
As of Dec 2024, Fulcrum Therapeutics, Inc. reports price-to-sales ratio of 3.6x. Track price-to-sales multiples to contextualize revenue-driven valuation swings and peer comparisons.
When to use price-to-sales
P/S is helpful for companies with slim or volatile profits. It shows how rich investors value each dollar of revenue.
Compare against industry norms
High-growth software firms command higher P/S ratios than retailers. Stack the metric versus sector averages to read sentiment.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
98%
Operating Margin
-27.4%
Net Profit Margin
-12.2%
Return on Equity
-4%
Return on Assets
-3.7%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Fulcrum Therapeutics, Inc. (FULC) FAQs
Answers tailored to Fulcrum Therapeutics, Inc.’s price-to-sales ratio profile using the latest Financial Modeling Prep data.
What is Fulcrum Therapeutics, Inc.'s current price-to-sales ratio?
As of Dec 2024, Fulcrum Therapeutics, Inc. reports price-to-sales ratio of 3.6x. This reading reflects the latest filings and price data for FULC.
How is Fulcrum Therapeutics, Inc.'s price-to-sales ratio trending year over year?
Year-over-year, the figure shifts by −143.9 (−97.5%). Pair this context with revenue growth and free cash flow signals to gauge momentum for FULC.
Why does price-to-sales ratio matter for Fulcrum Therapeutics, Inc.?
Price-to-sales compares market capitalization with revenue to assess valuation against top-line performance. For Fulcrum Therapeutics, Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Fulcrum Therapeutics, Inc.'s price-to-sales ratio above its recent average?
Fulcrum Therapeutics, Inc.'s rolling three-period average sits at 67.6x. Comparing the latest reading of 3.6x to that baseline highlights whether momentum is building or fading for FULC.
How frequently is Fulcrum Therapeutics, Inc.'s price-to-sales ratio refreshed?
Data for FULC was last refreshed on Dec 7, 2025, 2:51 AM and updates automatically every 24 hours, keeping your valuation inputs current.